- Home
- BHVN vs ADPT Comparison
BHVN vs ADPT Comparison
Compare BHVN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- ADPT
- Stock Information
- Founded
- BHVN 2013
- ADPT 2009
- Country
- BHVN United States
- ADPT United States
- Employees
- BHVN N/A
- ADPT N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHVN Health Care
- ADPT Health Care
- Exchange
- BHVN Nasdaq
- ADPT Nasdaq
- Market Cap
- BHVN 1.5B
- ADPT 1.8B
- IPO Year
- BHVN 2017
- ADPT 2019
- Fundamental
- Price
- BHVN $15.66
- ADPT $13.00
- Analyst Decision
- BHVN Strong Buy
- ADPT Strong Buy
- Analyst Count
- BHVN 14
- ADPT 8
- Target Price
- BHVN $54.62
- ADPT $12.38
- AVG Volume (30 Days)
- BHVN 2.3M
- ADPT 2.2M
- Earning Date
- BHVN 08-11-2025
- ADPT 08-05-2025
- Dividend Yield
- BHVN N/A
- ADPT N/A
- EPS Growth
- BHVN N/A
- ADPT N/A
- EPS
- BHVN N/A
- ADPT N/A
- Revenue
- BHVN N/A
- ADPT $205,216,000.00
- Revenue This Year
- BHVN N/A
- ADPT $24.39
- Revenue Next Year
- BHVN $1,007.82
- ADPT $20.44
- P/E Ratio
- BHVN N/A
- ADPT N/A
- Revenue Growth
- BHVN N/A
- ADPT 21.60
- 52 Week Low
- BHVN $12.79
- ADPT $3.98
- 52 Week High
- BHVN $55.70
- ADPT $13.40
- Technical
- Relative Strength Index (RSI)
- BHVN 56.24
- ADPT 64.48
- Support Level
- BHVN $14.23
- ADPT $12.10
- Resistance Level
- BHVN $16.14
- ADPT $13.37
- Average True Range (ATR)
- BHVN 0.86
- ADPT 0.87
- MACD
- BHVN 0.10
- ADPT 0.06
- Stochastic Oscillator
- BHVN 85.48
- ADPT 85.74
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).